Transverse striation needling for 30 cases of cervical spondylosis

目的:观察横纹针法治疗颈型颈椎病的临床疗效。方法:30例颈型颈椎病患者于2013年7月 ~; 2015年3月在厦大医院中山附属演武分院国医堂确诊并纳入。对该30名患者进行横纹针法治疗,即平刺颈椎间横纹处,并配合针刺常规穴位风池(双)、肩井; (双)和肩中俞(双),1次/天,2次/周,共6次。之后进行两个月后的随访。结果:30名患者中,显著有效率为70.0%(21/30),有效率为30; .0% (9/30),总有效率为100.0%。两个月内无复发病情。结论:横纹针法对颈型颈椎病有很好的治疗效果。Objective To observe the clinical efficacy of transverse striation; needling in treatment of cervical spondylosis. Method Thirty patients; were diagnosed with cervical spondylosis in Guoyitang Clinic, Yanwu; Branch of Zhongshan Hospital, Xiamen University from July, 2013 to; March, 2015, and were included into this study. Transverse striation; needling, i.e. transverse insertion into the transverse striation of the; cervical vertebra, was adopted for the 30 patients, and conventional; acupuncture at Fengchi(风池GB 20, bilateral), Jianjing(肩井GB 21,; bilateral)and Jianzhongshu(肩中俞SI 15, bilateral)was combined. The; treatment was conducted for once a day, twice a week, and 6 times were; needed in total. Follow-up visit was performed two months after the; treatment. Result Among the 30 patients, the markedly effective rate was; 70.0%(21/30), effective rate was 30.0%(9/30), and the total effective; rate was 100.0%. There was no relapse during two months after the; treatment. Conclusion The therapeutic eff ect of transverse striation; needling in treatment of cervical spondylosis was good

Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study

Background and aimsReal-world data regarding hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients receiving tenofovir alafenamide (TAF) as an antiviral drug are limited. Hence, we evaluated the efficacy and kidney safety of TAF among this population.MethodsA total of 272 HBV-related ACLF patients hospitalized at Xiangya Hospital of Central South University were enrolled in this retrospective research. All patients received antiviral therapy with TAF (n = 100) or ETV (n = 172) and comprehensive medical treatments.ResultsThrough 1:1 propensity score matching, 100 patients were finally included in each group. At week 48, the survival rates without transplantation of the TAF group and ETV group were 76.00 and 58.00%, separately (P = 0.007). After 4 weeks of treatment, the TAF treatment group exhibited a significantly decline in HBV DNA viral load (P = 0.029). The mean estimated glomerular filtration rate was apparently improved in the TAF group compared with the ETV group (TAF 5.98 ± 14.46 vs. ETV 1.18 ± 18.07 ml/min/1.73 m2) (P < 0.05). There were 6 patients in TAF group and 21 patients in ETV group with chronic kidney disease (CKD) stage progression ≥ 1. By contrast, the ETV treatment group has a greater risk of renal function progression in CKD 1 stage patients (P < 0.05).ConclusionThis real-world clinical study showed that TAF is more effective than ETV in reducing viral load and improving survival rate in HBV-ACLF patients and the risk of renal function decline is lower.Clinical trial registrationhttps://ClinicalTrials.gov, identifier NCT05453448